Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets

S. L. Schadinger, J. H H Lin, Mathieu Garand, M. B. Boffa

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The thrombin-activatable fibrinolysis inhibitor (TAFI) is a zymogen first characterized in human plasma that is activated through proteolytic cleavage by thrombin, thrombin in complex with thrombomodulin, or plasmin. Active TAFI attenuates fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin, thereby inhibiting a potent positive feedback loop in the fibrinolytic cascade. The existence of a separate pool of TAFI within platelets has been described. Objectives and Methods: We aimed to confirm the presence of TAFI in the medium of washed, thrombin-stimulated platelets and to evaluate the characteristics of platelet TAFI by western blot analysis and with a quantitative assay for activated TAFI. We also assessed the ability of platelet TAFI to inhibit fibrinolysis in vitro, using a platelet-rich thrombus lysis assay. Results: Our data are consistent with the presence of TAFI in the α-granules of resting platelets. In contrast to previous reports, platelet TAFI is very similar in electrophoretic mobility to plasma-derived TAFI. We also show, for the first time, that platelet-derived TAFI is capable of attenuating platelet-rich thrombus lysis in vitro independently of plasma TAFI. Moreover, we demonstrate additive effects on thrombolysis of platelet-derived TAFI and TAFI present in plasma. Conclusions: Taken together, these observations indicate that the secretion of platelet-derived TAFI can augment the concentrations of TAFI already present in plasma to enhance attenuation of the fibrinolytic cascade. This could be significant in regions of vascular damage or pathologic thrombosis, where activated platelets are known to accumulate.

Original languageEnglish
Pages (from-to)2523-2529
Number of pages7
JournalJournal of Thrombosis and Haemostasis
Volume8
Issue number11
DOIs
Publication statusPublished - 1 Nov 2010
Externally publishedYes

Fingerprint

Carboxypeptidase B2
Antifibrinolytic Agents
Blood Platelets
Thrombin
Thrombosis
Fibrinolysis
Thrombomodulin

Keywords

  • α-granules
  • Carboxypeptidases
  • Fibrinolysis
  • Platelets
  • TAFI

ASJC Scopus subject areas

  • Hematology

Cite this

Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. / Schadinger, S. L.; Lin, J. H H; Garand, Mathieu; Boffa, M. B.

In: Journal of Thrombosis and Haemostasis, Vol. 8, No. 11, 01.11.2010, p. 2523-2529.

Research output: Contribution to journalArticle

@article{593e3a9b024b4ab9bc13074566824151,
title = "Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets",
abstract = "The thrombin-activatable fibrinolysis inhibitor (TAFI) is a zymogen first characterized in human plasma that is activated through proteolytic cleavage by thrombin, thrombin in complex with thrombomodulin, or plasmin. Active TAFI attenuates fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin, thereby inhibiting a potent positive feedback loop in the fibrinolytic cascade. The existence of a separate pool of TAFI within platelets has been described. Objectives and Methods: We aimed to confirm the presence of TAFI in the medium of washed, thrombin-stimulated platelets and to evaluate the characteristics of platelet TAFI by western blot analysis and with a quantitative assay for activated TAFI. We also assessed the ability of platelet TAFI to inhibit fibrinolysis in vitro, using a platelet-rich thrombus lysis assay. Results: Our data are consistent with the presence of TAFI in the α-granules of resting platelets. In contrast to previous reports, platelet TAFI is very similar in electrophoretic mobility to plasma-derived TAFI. We also show, for the first time, that platelet-derived TAFI is capable of attenuating platelet-rich thrombus lysis in vitro independently of plasma TAFI. Moreover, we demonstrate additive effects on thrombolysis of platelet-derived TAFI and TAFI present in plasma. Conclusions: Taken together, these observations indicate that the secretion of platelet-derived TAFI can augment the concentrations of TAFI already present in plasma to enhance attenuation of the fibrinolytic cascade. This could be significant in regions of vascular damage or pathologic thrombosis, where activated platelets are known to accumulate.",
keywords = "α-granules, Carboxypeptidases, Fibrinolysis, Platelets, TAFI",
author = "Schadinger, {S. L.} and Lin, {J. H H} and Mathieu Garand and Boffa, {M. B.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1111/j.1538-7836.2010.04024.x",
language = "English",
volume = "8",
pages = "2523--2529",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets

AU - Schadinger, S. L.

AU - Lin, J. H H

AU - Garand, Mathieu

AU - Boffa, M. B.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The thrombin-activatable fibrinolysis inhibitor (TAFI) is a zymogen first characterized in human plasma that is activated through proteolytic cleavage by thrombin, thrombin in complex with thrombomodulin, or plasmin. Active TAFI attenuates fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin, thereby inhibiting a potent positive feedback loop in the fibrinolytic cascade. The existence of a separate pool of TAFI within platelets has been described. Objectives and Methods: We aimed to confirm the presence of TAFI in the medium of washed, thrombin-stimulated platelets and to evaluate the characteristics of platelet TAFI by western blot analysis and with a quantitative assay for activated TAFI. We also assessed the ability of platelet TAFI to inhibit fibrinolysis in vitro, using a platelet-rich thrombus lysis assay. Results: Our data are consistent with the presence of TAFI in the α-granules of resting platelets. In contrast to previous reports, platelet TAFI is very similar in electrophoretic mobility to plasma-derived TAFI. We also show, for the first time, that platelet-derived TAFI is capable of attenuating platelet-rich thrombus lysis in vitro independently of plasma TAFI. Moreover, we demonstrate additive effects on thrombolysis of platelet-derived TAFI and TAFI present in plasma. Conclusions: Taken together, these observations indicate that the secretion of platelet-derived TAFI can augment the concentrations of TAFI already present in plasma to enhance attenuation of the fibrinolytic cascade. This could be significant in regions of vascular damage or pathologic thrombosis, where activated platelets are known to accumulate.

AB - The thrombin-activatable fibrinolysis inhibitor (TAFI) is a zymogen first characterized in human plasma that is activated through proteolytic cleavage by thrombin, thrombin in complex with thrombomodulin, or plasmin. Active TAFI attenuates fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin, thereby inhibiting a potent positive feedback loop in the fibrinolytic cascade. The existence of a separate pool of TAFI within platelets has been described. Objectives and Methods: We aimed to confirm the presence of TAFI in the medium of washed, thrombin-stimulated platelets and to evaluate the characteristics of platelet TAFI by western blot analysis and with a quantitative assay for activated TAFI. We also assessed the ability of platelet TAFI to inhibit fibrinolysis in vitro, using a platelet-rich thrombus lysis assay. Results: Our data are consistent with the presence of TAFI in the α-granules of resting platelets. In contrast to previous reports, platelet TAFI is very similar in electrophoretic mobility to plasma-derived TAFI. We also show, for the first time, that platelet-derived TAFI is capable of attenuating platelet-rich thrombus lysis in vitro independently of plasma TAFI. Moreover, we demonstrate additive effects on thrombolysis of platelet-derived TAFI and TAFI present in plasma. Conclusions: Taken together, these observations indicate that the secretion of platelet-derived TAFI can augment the concentrations of TAFI already present in plasma to enhance attenuation of the fibrinolytic cascade. This could be significant in regions of vascular damage or pathologic thrombosis, where activated platelets are known to accumulate.

KW - α-granules

KW - Carboxypeptidases

KW - Fibrinolysis

KW - Platelets

KW - TAFI

UR - http://www.scopus.com/inward/record.url?scp=78149277497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149277497&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2010.04024.x

DO - 10.1111/j.1538-7836.2010.04024.x

M3 - Article

C2 - 20723026

AN - SCOPUS:78149277497

VL - 8

SP - 2523

EP - 2529

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 11

ER -